Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results
Silence Therapeutics (SLN) reported Q3 2026 financial results, including $247.7M in cash, $12.4M net loss, and reduced R&D expenses. The company announced positive Phase 2 trial results for divesiran and an agreement to be acquired by Merck KGaA, expected to close in Q1 2027. Total shares outstanding were 186.6M as of September 30, 2026.
How this was made
The 30-second read
Why it matters
The acquisition provides a clear catalyst for SLN shareholders, while the Q3 financials show improved cash position and reduced losses.
Market read
The deal adds a premium to SLN and underscores ongoing M&A activity in the RNA therapeutics space.
What to watch
Merck KGaA's financing terms and post‑acquisition execution risk are not detailed.
Background
Silence Therapeutics, a clinical‑stage siRNA company, reported Q3 2026 results and disclosed a pending acquisition by Merck KGaA.
Ticker impact
Silence Therapeutics announced a definitive agreement to be acquired by Merck KGaA, pending closing in Q1 2027.
upward pressure as market prices acquisition premium
The deal is a fresh primary disclosure with a clear premium, creating immediate buying interest.
Market effects
May spur further consolidation in the biotech/siRNA sector as larger firms seek pipeline assets.
Highlights activity in the UK biotech market where Silence is headquartered.
Signals continued interest from large pharma in RNA‑based therapeutics worldwide.
Counterpoint
Deal could face regulatory scrutiny or integration challenges, potentially limiting upside.
Key entities
- companySilence Therapeutics
Clinical‑stage biotech developing siRNA therapies.
- companyMerck KGaA
German pharmaceutical group acquiring Silence.
